Fred Saad

107.6k total citations · 17 hit papers
1.2k papers, 36.7k citations indexed

About

Fred Saad is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Fred Saad has authored 1.2k papers receiving a total of 36.7k indexed citations (citations by other indexed papers that have themselves been cited), including 937 papers in Pulmonary and Respiratory Medicine, 494 papers in Oncology and 324 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Fred Saad's work include Prostate Cancer Treatment and Research (786 papers), Prostate Cancer Diagnosis and Treatment (317 papers) and Radiopharmaceutical Chemistry and Applications (304 papers). Fred Saad is often cited by papers focused on Prostate Cancer Treatment and Research (786 papers), Prostate Cancer Diagnosis and Treatment (317 papers) and Radiopharmaceutical Chemistry and Applications (304 papers). Fred Saad collaborates with scholars based in Canada, United States and Germany. Fred Saad's co-authors include Karim Fizazi, Neal D. Shore, Johann S. de Bono, Cora N. Sternberg, Kim N., Allan Lipton, Paul N. Mainwaring, Anne‐Marie Mes‐Masson, Pierre I. Karakiewicz and Howard I. Scher and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Fred Saad

1.2k papers receiving 36.1k citations

Hit Papers

Increased Survival with E... 2002 2026 2010 2018 2012 2020 2002 2012 2018 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
    2012 3.3k citations Howard I. Scher, Karim Fizazi et al. profile →
  2. Olaparib for Metastatic Castration-Resistant Prostate Cancer
    2020 1.4k citations Johann S. de Bono, Karim Fizazi et al. profile →
  3. A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma
    2002 1.2k citations Fred Saad et al. profile →
  4. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
    2012 1.0k citations Karim Fizazi, Howard I. Scher et al. profile →
  5. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
    2018 868 citations Matthew R. Smith, Fred Saad et al. profile →
  6. Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer
    2009 786 citations Matthew Smith, Fred Saad et al. profile →
  7. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
    2018 677 citations Karim Fizazi, Fred Saad et al. profile →
  8. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases
    2011 571 citations Fred Saad, Janet E. Brown et al. Annals of Oncology profile →
  9. Pathologic fractures correlate with reduced survival in patients with malignant bone disease
    2007 492 citations Fred Saad, Allan Lipton et al. Cancer profile →
  10. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
    2020 474 citations Karim Fizazi, Fred Saad et al. profile →
  11. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
    2012 420 citations Allan Lipton, Karim Fizazi et al. profile →
  12. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial
    2018 281 citations Fred Saad et al. profile →
  13. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
    2020 266 citations Karim Fizazi, Fred Saad et al. profile →
  14. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
    2020 259 citations Neal D. Shore, Fred Saad et al. profile →
  15. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial
    2021 183 citations Johann S. de Bono, Celestia S. Higano et al. profile →
  16. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
    2023 132 citations Fred Saad, Neal D. Shore et al. profile →
  17. Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial
    2023 99 citations Bertrand Tombal, Fred Saad et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Fred Saad 23.9k 15.4k 8.7k 7.6k 6.9k 1.2k 36.7k
Karim Fizazi 25.3k 1.1× 14.8k 1.0× 9.9k 1.1× 6.5k 0.9× 8.0k 1.2× 835 36.7k
Neal D. Shore 17.0k 0.7× 9.5k 0.6× 5.6k 0.6× 4.9k 0.6× 4.8k 0.7× 768 25.3k
Eric J. Small 24.2k 1.0× 14.3k 0.9× 6.7k 0.8× 8.9k 1.2× 8.3k 1.2× 613 35.7k
Nicholas J. Vogelzang 22.7k 0.9× 17.2k 1.1× 5.5k 0.6× 8.4k 1.1× 6.5k 0.9× 701 41.8k
Stéphane Oudard 27.5k 1.1× 13.8k 0.9× 4.9k 0.6× 16.5k 2.2× 12.0k 1.7× 618 38.8k
Cora N. Sternberg 21.0k 0.9× 12.1k 0.8× 5.0k 0.6× 7.6k 1.0× 6.6k 1.0× 583 34.5k
Mario A. Eisenberger 21.3k 0.9× 8.5k 0.5× 6.1k 0.7× 5.1k 0.7× 6.4k 0.9× 380 27.2k
Michael Gnant 5.6k 0.2× 13.1k 0.8× 3.5k 0.4× 7.8k 1.0× 10.0k 1.4× 555 37.9k
Allan Lipton 5.0k 0.2× 15.7k 1.0× 5.8k 0.7× 4.8k 0.6× 2.1k 0.3× 411 21.3k
Giorgio V. Scagliotti 19.6k 0.8× 17.1k 1.1× 2.2k 0.2× 8.4k 1.1× 5.3k 0.8× 480 29.7k

Countries citing papers authored by Fred Saad

Since Specialization
Citations

This map shows the geographic impact of Fred Saad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fred Saad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fred Saad more than expected).

Fields of papers citing papers by Fred Saad

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fred Saad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fred Saad. The network helps show where Fred Saad may publish in the future.

Co-authorship network of co-authors of Fred Saad

This figure shows the co-authorship network connecting the top 25 collaborators of Fred Saad. A scholar is included among the top collaborators of Fred Saad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fred Saad. Fred Saad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
So, Alan, Kim Chi, Brita Danielson, et al.. (2025). 2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-naive and castrationsensitive prostate cancer (Update). Canadian Urological Association Journal. 19(5). E142–52.
2.
Angelis, Mario de, Andrea Baudo, Carolin Siech, et al.. (2024). The effect of race/ethnicity on cancer-specific mortality after trimodal therapy. Journal of Racial and Ethnic Health Disparities. 12(3). 1416–1422. 5 indexed citations
3.
4.
5.
Tutrone, Ronald, Fred Saad, Daniel J. George, et al.. (2023). Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. European Urology Oncology. 7(4). 906–913. 6 indexed citations
6.
Sandhu, Shahneen, Geoffrey Gotto, Francisco Vera-Badillo, et al.. (2023). 1835P A prospective study to determine the prevalence of DNA repair defects in patients (pts) with advanced prostate cancer (PC). Annals of Oncology. 34. S993–S993. 2 indexed citations
7.
Posadas, Edwin M., Kim N., Ronald de Wit, et al.. (2020). Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study. Clinical Cancer Research. 26(14). 3517–3524. 12 indexed citations
8.
Fendler, Wolfgang P., Manuel Weber, Amir Iravani, et al.. (2019). Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 25(24). 7448–7454. 183 indexed citations
9.
Gulley, James L., Michael Borre, Nicholas J. Vogelzang, et al.. (2019). Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 37(13). 1051–1061. 183 indexed citations
10.
Tagawa, Scott T., Emmanuel S. Antonarakis, Ada Gjyrezi, et al.. (2018). Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY. Clinical Cancer Research. 25(6). 1880–1888. 86 indexed citations
11.
Heller, Glenn, Karim Fizazi, Robert G. McCormack, et al.. (2016). The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population. Clinical Cancer Research. 23(8). 1967–1973. 43 indexed citations
12.
Lipton, Allan, Matthew Smith, Karim Fizazi, et al.. (2016). Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents. Clinical Cancer Research. 22(23). 5713–5721. 32 indexed citations
13.
Charlebois, Roxanne, Guillaume Chouinard, Bertrand Allard, et al.. (2015). CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer. Clinical Cancer Research. 22(1). 158–166. 162 indexed citations
14.
Ryan, Charles J., Kim Stuyckens, Matthew R. Smith, et al.. (2015). Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate–Treated Castration-Resistant Prostate Cancer Patients. Clinical Cancer Research. 21(14). 3170–3177. 50 indexed citations
15.
Basch, Ethan, D.A. Loblaw, Thomas K. Oliver, et al.. (2014). Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline. Journal of Clinical Oncology. 32(30). 3436–3448. 165 indexed citations
16.
Pra, Alan Dal, Emilie Lalonde, Jenna Sykes, et al.. (2013). TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair. Clinical Cancer Research. 19(18). 5202–5209. 33 indexed citations
17.
El-Assaad, Wissal, Xue Qing David Wang, Véronique Barrès, et al.. (2012). p53 Inhibits Angiogenesis by Inducing the Production of Arresten. Cancer Research. 72(5). 1270–1279. 52 indexed citations
18.
Lessard, Laurent, David P. Labbé, Geneviève Deblois, et al.. (2012). PTP1B Is an Androgen Receptor–Regulated Phosphatase That Promotes the Progression of Prostate Cancer. Cancer Research. 72(6). 1529–1537. 69 indexed citations
19.
Furic, Luc, Liwei Rong, Ola Larsson, et al.. (2010). eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proceedings of the National Academy of Sciences. 107(32). 14134–14139. 398 indexed citations
20.
Saad, Fred, Jonathan D. Adachi, Jacques P. Brown, et al.. (2008). Cancer Treatment–Induced Bone Loss in Breast and Prostate Cancer. Journal of Clinical Oncology. 26(33). 5465–5476. 134 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karim Fizazi Breakdown of academic impact, for papers by Neal D. Shore Breakdown of academic impact, for papers by Eric J. Small Breakdown of academic impact, for papers by Nicholas J. Vogelzang Breakdown of academic impact, for papers by Stéphane Oudard Breakdown of academic impact, for papers by Cora N. Sternberg Breakdown of academic impact, for papers by Mario A. Eisenberger Breakdown of academic impact, for papers by Michael Gnant Breakdown of academic impact, for papers by Allan Lipton Breakdown of academic impact, for papers by Giorgio V. Scagliotti
Rankless by CCL
2026